Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

PCVX

Vaxcyte Inc

Nov 12 • 04:00PM ET

46.10

+0.44 0.96 %

Healthcare • Biotechnology • USA • NASD

Peers: PFE MRNA BNTX NVAX AZN JNJ GSK ALNY NVCR VNDA

| Held by: VTI IWM VB XBI VBK VXF IWN IBB SCHA VTWO

Index	RUT	P/E	-	EPS (ttm)	-4.92	Insider Own	3.43%	Shs Outstand	130.03M	Perf Week	14.34%
Market Cap	6.03B	Forward P/E	-	EPS next Y	-5.96	Insider Trans	0.00%	Shs Float	126.42M	Perf Month	7.58%
Enterprise Value	4.41B	PEG	-	EPS next Q	-1.46	Inst Own	110.85%	Short Float	6.78%	Perf Quarter	46.68%
Income	-657.20M	P/S	-	EPS this Y	-38.05%	Inst Trans	2.35%	Short Ratio	5.06	Perf Half Y	56.70%
Sales	0.00M	P/B	2.07	EPS next Y	-13.59%	ROA	-19.53%	Short Interest	8.57M	Perf YTD	-43.68%
Book/sh	22.25	P/C	3.53	EPS next 5Y	-19.27%	ROE	-20.83%	52W High	103.30 -55.37%	Perf Year	-56.78%
Cash/sh	13.07	P/FCF	-	EPS past 3/5Y	-25.42% -29.88%	ROIC	-22.12%	52W Low	27.66 66.67%	Perf 3Y	6.34%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.44% 4.78%	Perf 5Y	22.61%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-5.21%	Oper. Margin	-	ATR (14)	2.09	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	8.83	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	64.02	Recom	1.20
Dividend Gr. 3/5Y	- -	Current Ratio	8.83	EPS Q/Q	-87.44%	SMA20	6.86%	Beta	1.29	Target Price	98.00
Payout	-	Debt/Eq	0.03	Sales Q/Q	-	SMA50	18.51%	Rel Volume	0.67	Prev Close	45.66
Employees	414	LT Debt/Eq	0.03	Earnings	Nov 04 AMC	SMA200	4.64%	Avg Volume	1.69M	Price	46.10
IPO	Jun 12, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-26.03% -	Trades		Volume	1,151,501	Change	0.96%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-12-25	Initiated	Goldman	Neutral	$38
Apr-22-25	Initiated	Cantor Fitzgerald	Overweight
Dec-20-24	Initiated	Goldman	Buy	$135
Dec-07-23	Initiated	Mizuho	Buy	$69
Apr-18-23	Initiated	TD Cowen	Outperform
Jan-03-23	Reiterated	Needham	Buy	$52 → $58
Dec-15-22	Initiated	Guggenheim	Buy	$66
Nov-17-22	Initiated	BTIG Research	Buy	$69
Dec-29-21	Resumed	Jefferies	Buy	$50
Jun-24-21	Resumed	Jefferies	Buy	$50
Jul-07-20	Initiated	Needham	Buy	$40
Jul-07-20	Initiated	Cantor Fitzgerald	Overweight	$55
Jul-07-20	Initiated	BofA Securities	Buy	$37

Show Previous Ratings

Nov-10-25 08:16PM	TD Cowen Reiterates "Buy" Rating on Vaxcyte (PCVX) With $50 PT (Insider Monkey) +6.38%
Nov-04-25 04:05PM	Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study (GlobeNewswire)
Oct-08-25 12:57AM	Bank of America Securities Maintains a Buy Rating on Vaxcyte (PCVX) (Insider Monkey)
Sep-30-25 02:49PM	What Does Wall Street Think About Vaxcyte (PCVX)? (Insider Monkey)
08:30AM	Vaxcyte to Establish Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy Representing Up to $1 Billion in Manufacturing and Services (GlobeNewswire)
04:12AM	Loading…
04:12AM	Vaxcyte, Inc. (PCVX) Announces Progress in its VAX-31 Infant Vaccine Study (Insider Monkey)
Sep-12-25 08:55AM	TSCM U.S. Small Cap Growth Strategy Exited Vaxcyte (PCVX) as Its Infant Trial was Less Than Compelling (Insider Monkey)
Sep-03-25 07:30AM	Vaxcyte Advances VAX-31 Infant Phase 2 Dose-Finding Study with First Participants Receiving VAX-31 Optimized Dose (GlobeNewswire)
Aug-06-25 04:05PM	Vaxcyte Reports Second Quarter 2025 Financial Results and Provides Business Update, Highlighting Key Clinical and Regulatory Progress for VAX-31, a Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) (GlobeNewswire) -9.06%
Jul-31-25 11:35AM	Vaxcyte, Inc. (PCVX)'s VAX-24 Achieves Phase 2 Success in Infants (Insider Monkey)
Jul-16-25 09:38AM	Mizuho Maintains an Overweight Rating on Vaxcyte (PCVX) (Insider Monkey)
Jul-08-25 08:17AM	Here's Why Vaxcyte (PCVX) Sold Off in Q1 (Insider Monkey)
Jul-02-25 02:47AM	Cantor Fitzgerald Maintains Overweight on Vaxcyte Amid Vaccine Development and ACIP Meeting (Insider Monkey)
May-27-25 09:08AM	Here's Why Vaxcyte (PCVX) Sold Off in Q1 (Insider Monkey)
May-09-25 09:03AM	Is Vaxcyte, Inc. (PCVX) The Best Stock That Will Bounce Back? (Insider Monkey)
04:01PM	Loading…
May-07-25 04:01PM	Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) +8.45%
04:55AM	Fidelity Select Health Care Portfolio Q1 2025 Commentary (Seeking Alpha)
May-03-25 05:30AM	Franklin Growth Opportunities SMA Q1 2025 Commentary (Seeking Alpha)
May-01-25 08:00AM	Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors (GlobeNewswire)
Apr-30-25 06:33PM	Hope Amidst The Madness As Market Avoids A New Low (Seeking Alpha)
Apr-29-25 08:24PM	Is Vaxcyte, Inc. (PCVX) the Best Oversold NASDAQ Stock to Buy Right Now? (Insider Monkey) +5.68%
Apr-11-25 04:21PM	Vaxcyte, Inc. (PCVX): Billionaire Stanley Druckenmiller's Top Stock Pick with Huge Upside Potential (Insider Monkey) +11.27%
Apr-10-25 01:07PM	Vaxcyte Stock Plummets 56% in a Month: Here's the Reason (Zacks) -8.96%
Apr-07-25 08:00AM	ClearBridge Small Cap Growth Strategy Q1 2025 Commentary (Seeking Alpha)
Apr-05-25 11:00AM	Markets Watch Out For Core CPI With Big Banks Set To Report Earnings (Seeking Alpha)
Apr-01-25 12:45PM	Vaxcyte narrow misses in Phase 2 likely to be ok in Phase 3, says Evercore ISI (TipRanks) -14.65%
12:16PM	Rocket acquires Mr. Cooper, Musks xAI acquires X: Morning Buzz (TipRanks)
07:23AM	Biotech Stocks Fall After Top FDA Official Quits Over Clash With RFK Jr. (Zacks)
07:19AM	Vaxcyte stock sinks despite Phase II IPD vaccine trial success (Clinical Trials Arena)
Mar-31-25 05:20PM	Vaxcyte: Shares Tanking On Positive Data? Bad Time To Be A Vaccine Developer (Seeking Alpha) -45.64%
04:12PM	Loading…
04:12PM	Biotechs Hammered After FDA Official Resigns, Citing RFK Jr.'s 'Misinformation And Lies' (Investor's Business Daily)
03:39PM	Vaxcyte: Plunge On FDA Top Regulator Resigning Generates Buying Opportunity (Seeking Alpha)
09:57AM	Moderna, biotech stocks slide on resignation of FDA official Peter Marks (Yahoo Finance)
09:57AM	Moderna, biotech stocks slide following resignation of FDA official Peter Marks (Yahoo Finance)
09:45AM	Moderna, Vaxcyte, Novavax Hammered After Key FDA Official Peter Marks Resigns (Investor's Business Daily)
07:00AM	Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study (GlobeNewswire)
Mar-30-25 06:30PM	Vaxcyte, Inc. (PCVX): One of the Best Debt Free Mid Cap Stocks to Buy Now (Insider Monkey)
05:00PM	Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study (GlobeNewswire)
04:08PM	Why Vaxcyte, Inc. (PCVX) Is Among the Best Mid Cap Biotech Stocks to Buy (Insider Monkey)
Mar-27-25 11:34AM	Merck Gets EC Nod for 21-Valent Pneumococcal Jab Capvaxive (Zacks)
09:44AM	Is Vaxcyte, Inc. (PCVX) the Best Up and Coming Stock to Buy According to Wall Street Analysts? (InsiderMonkey)
Mar-25-25 08:02AM	Vaxcyte (PCVX) Struggled Amid Political Uncertainty (InsiderMonkey)
Mar-20-25 12:00PM	Lazard US Equity Concentrated Portfolio Q4 2024 Commentary (SeekingAlpha)
Mar-07-25 05:35AM	Goldman Sachs Says Its Time to Pull the Trigger on Healthcare Stocks Here Are 2 Names to Pounce on Now (TipRanks)
Mar-03-25 06:50PM	Vaxcyte, Inc. (PCVX): Among the Cash-Rich Mid Cap Stocks to Buy Now (Insider Monkey)
Feb-26-25 11:03AM	Why Vaxcyte, Inc. (PCVX) Is One of the Best Vaccine Stocks to Buy According to Hedge Funds (Insider Monkey)
07:26AM	Q4 2024 Vaxcyte Inc Earnings Call (Thomson Reuters StreetEvents)
02:15AM	Vaxcyte Inc (PCVX) Q4 2024 Earnings Call Highlights: Strong Financial Health and Promising ... (GuruFocus.com)
Feb-25-25 04:01PM	Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
12:30PM	Vaxcyte, Inc. (PCVX): Among the Stocks That Will Go to The Moon According to Analysts (Insider Monkey)
Feb-13-25 04:14PM	It's Official: The Senate Will Let Robert F. Kennedy Jr. 'Go Wild' On Health Care (Investor's Business Daily)
Feb-12-25 04:05PM	Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025 (GlobeNewswire)
01:25PM	RFK Jr. Confirmation Looms. How Kennedy Could 'Go Wild' On Health Care. (Investor's Business Daily)
Feb-08-25 09:22AM	Why Vaxcyte, Inc. (PCVX) Is Among the Best Healthcare Stocks To Buy According to Analysts (Insider Monkey)
Feb-06-25 08:20AM	Vaxcyte advances second stage of Phase 2 study evaluating VAX-31 (TipRanks)
07:22AM	Vaxcyte enters final stage of Phase II pneumococcal vaccine trial in infants (Clinical Trials Arena)
Feb-05-25 08:00AM	Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants (GlobeNewswire)
Jan-30-25 04:05PM	Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference (GlobeNewswire)
Jan-18-25 05:50PM	Why Vaxcyte, Inc. (PCVX) Is One of the Best Russell 2000 Stocks to Invest in According to Analysts? (Insider Monkey)
Dec-23-24 10:11AM	Is Vaxcyte, Inc. (PCVX) the Best Performing Biotech Stock in 2024? (Insider Monkey)
Dec-09-24 07:57AM	What Makes Vaxcyte (PCVX) An Investment Bet? (Insider Monkey)
Dec-04-24 10:03AM	Vaxcyte doses first subject in pneumococcal conjugate vaccine trial in infants (Clinical Trials Arena)
Dec-03-24 08:00AM	Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants (GlobeNewswire)
Nov-27-24 09:29AM	Vaxcyte (PCVX) Surged On Positive Phase 2 Data For Its Drug (Insider Monkey)
Nov-12-24 07:30AM	Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs (GlobeNewswire)
Nov-06-24 12:09AM	Decoding Vaxcyte Inc (PCVX): A Strategic SWOT Insight (GuruFocus.com)
Nov-05-24 04:01PM	Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Nov-01-24 09:13AM	Should You Consider Investing in Vaxcyte (PCVX)? (Insider Monkey)
Sep-14-24 07:47PM	Vaxcyte, Inc. (PCVX): Among Hedge Funds Top Biotech Stock Picks (Insider Monkey)
Sep-11-24 04:05PM	Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference (GlobeNewswire)
Sep-06-24 04:05PM	Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
07:00AM	Obesity drug startup raises $67M; Vors shielded transplant shows promise (BioPharma Dive)
Sep-04-24 11:58PM	Vaxcyte Announces Pricing of $1.3 Billion Public Offering (GlobeNewswire)
Sep-03-24 06:06PM	Vaccine Maker Raising $1 Billion Leads Post-Holiday Share Sales (Bloomberg) +36.39%
04:09PM	Vaxcyte Catapults As It Looks To Take On Pfizer, Merck In A Massive Market (Investor's Business Daily)
04:01PM	Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
01:22PM	Heard on the Street: Pfizer Better Watch Out for This Biotech (The Wall Street Journal)
11:43AM	Biotech Startup Vaxcyte Is a Threat to Pfizer and Merck. A Vaccine Candidate Is Why. (Barrons.com)
10:48AM	Look Out, Pfizer and Merck. Vaxcyte Posts Strong Pneumococcal Vaccine Data. (Barrons.com)
09:40AM	Bacterial Infections Vaccine Developer Vaxcyte's Pneumococcal Shot Shows Promise in Mid-Stage Trial, Stock Shoots Higher (Benzinga)
09:07AM	Vaxcyte Catapults 34% As It Looks To Take On Pfizer In A $10 Billion Market (Investor's Business Daily)
08:10AM	Vaxcytes best-case data for pneumococcal vaccine boost shares (BioPharma Dive)
07:07AM	Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older (GlobeNewswire)
Sep-02-24 06:40PM	Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older (GlobeNewswire)
Aug-06-24 04:05PM	Vaxcyte Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Aug-05-24 07:02PM	Insider Sale: COO Jim Wassil Sells 3,000 Shares of Vaxcyte Inc (PCVX) (GuruFocus.com)
Jul-31-24 09:55AM	Wall Street Analysts See a 25.16% Upside in Vaxcyte (PCVX): Can the Stock Really Move This High? (Zacks)
Jul-29-24 12:00PM	Are You Looking for a Top Momentum Pick? Why Vaxcyte, Inc. (PCVX) is a Great Choice (Zacks)
Jul-02-24 07:01PM	Insider Sale: COO Jim Wassil Sells 3,000 Shares of Vaxcyte Inc (PCVX) (GuruFocus.com)
08:30AM	Vaxcyte Appoints John Furey to Board of Directors (GlobeNewswire)
May-10-24 12:32PM	Vaxcyte Inc (PCVX) Reports Q1 2024 Earnings: A Detailed Financial and Operational Overview (GuruFocus.com)
May-08-24 10:55PM	PCVX Stock Earnings: Vaxcyte Beats EPS for Q1 2024 (InvestorPlace)
04:05PM	Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-04-24 02:31AM	Insider Sale at Vaxcyte Inc: COO Jim Wassil Sells 3,000 Shares (GuruFocus.com)
Apr-22-24 04:46PM	Vaxcyte Insider Sold Shares Worth $490,199, According to a Recent SEC Filing (MT Newswires)
Apr-02-24 04:05PM	Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-26-24 09:02PM	Sutro Biopharma Inc (STRO) Earnings: A Mixed Bag Amidst Strategic Advances (GuruFocus.com)
Mar-20-24 07:01PM	Insider Sell: Vaxcyte Inc (PCVX) CFO Andrew Guggenhime Sells 8,000 Shares (GuruFocus.com)
Mar-17-24 08:50AM	30 Biggest Biotechnology Companies in the World (Insider Monkey)
Mar-04-24 08:30AM	Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants (GlobeNewswire)

Vaxcyte, Inc. engages in the development of vaccines for infectious diseases. It focuses on conjugate vaccines and protein-based vaccines developed through the Sutro Biopharma's Xpress CF Platform, a cell-free protein synthesis technology. The company was founded by Grant E. Pickering and Jeff Fairman on November 27, 2013, and is headquartered in San Carlos, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lukatch Heath	Director	Apr 08 '25	Option Exercise	16.78	7,000	117,490	14,175	Apr 10 08:06 AM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Apr 07 '25	Option Exercise	20.93	4,777	99,983	131,950	Apr 09 08:05 AM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Apr 04 '25	Option Exercise	8.96	20,533	183,888	518,775	Apr 07 07:38 AM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Mar 05 '25	Option Exercise	21.41	5,000	107,050	46,620	Mar 07 04:43 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Mar 05 '25	Sale	70.74	5,000	353,699	41,620	Mar 07 04:43 PM
Eydelman Mikhail	Officer	Mar 05 '25	Proposed Sale	68.87	5,000	344,350		Mar 05 04:10 PM
Wassil Jim	CHIEF OPERATING OFFICER	Mar 03 '25	Option Exercise	4.38	8,000	35,071	162,931	Mar 03 09:14 PM
Wassil Jim	CHIEF OPERATING OFFICER	Mar 03 '25	Sale	73.27	8,000	586,165	154,931	Mar 03 09:14 PM
Wassil Jim	Officer	Mar 03 '25	Proposed Sale	73.17	8,000	585,360		Mar 03 04:06 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Feb 18 '25	Option Exercise	5.35	8,000	42,800	117,491	Feb 19 06:04 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Feb 18 '25	Sale	83.85	8,000	670,823	109,491	Feb 19 06:04 PM
GUGGENHIME ANDREW	Officer	Feb 18 '25	Proposed Sale	102.08	8,000	816,640		Feb 18 04:29 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Feb 05 '25	Option Exercise	21.41	5,000	107,050	33,222	Feb 07 04:04 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Feb 05 '25	Sale	90.07	5,000	450,369	28,222	Feb 07 04:04 PM
Eydelman Mikhail	Officer	Feb 05 '25	Proposed Sale	87.53	5,000	437,650		Feb 05 04:01 PM
Wassil Jim	CHIEF OPERATING OFFICER	Feb 03 '25	Option Exercise	2.42	8,000	19,360	213,695	Feb 04 07:20 PM
Wassil Jim	CHIEF OPERATING OFFICER	Feb 03 '25	Sale	86.22	8,000	689,790	205,695	Feb 04 07:20 PM
Wassil Jim	Officer	Feb 03 '25	Proposed Sale	88.20	8,000	705,600		Feb 03 04:05 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Jan 21 '25	Option Exercise	5.35	8,000	42,800	117,491	Jan 22 06:18 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Jan 21 '25	Sale	86.51	8,000	692,101	109,491	Jan 22 06:18 PM
GUGGENHIME ANDREW	Officer	Jan 21 '25	Proposed Sale	86.06	8,000	688,480		Jan 21 04:04 PM
Loxam Teri	Director	Jan 15 '25	Option Exercise	22.70	6,250	141,875	13,425	Jan 17 04:05 PM
Loxam Teri	Director	Jan 15 '25	Sale	85.11	6,250	531,963	7,175	Jan 17 04:05 PM
Loxam Teri	Director	Jan 15 '25	Proposed Sale	80.32	6,250	502,000		Jan 15 04:04 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Jan 06 '25	Option Exercise	21.41	5,000	107,050	33,222	Jan 07 04:33 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Jan 06 '25	Sale	85.58	5,000	427,923	28,222	Jan 07 04:33 PM
Eydelman Mikhail	Officer	Jan 06 '25	Proposed Sale	84.23	5,000	421,150		Jan 06 04:02 PM
Wassil Jim	CHIEF OPERATING OFFICER	Jan 02 '25	Option Exercise	2.42	8,000	19,360	213,695	Jan 03 06:07 PM
Wassil Jim	CHIEF OPERATING OFFICER	Jan 02 '25	Sale	83.66	8,000	669,267	205,695	Jan 03 06:07 PM
Wassil Jim	Officer	Jan 02 '25	Proposed Sale	82.64	8,000	661,120		Jan 02 04:10 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Dec 18 '24	Option Exercise	5.35	8,000	42,800	117,491	Dec 19 04:07 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Dec 18 '24	Sale	88.78	8,000	710,249	109,491	Dec 19 04:07 PM
Cowan Elvia	SVP, FINANCE	Dec 16 '24	Option Exercise	25.92	7,716	199,999	19,294	Dec 18 04:13 PM
GUGGENHIME ANDREW	Officer	Dec 18 '24	Proposed Sale	89.83	8,000	718,640		Dec 18 04:03 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Dec 09 '24	Sale	92.25	2,366	218,253	136,215	Dec 10 04:10 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Dec 05 '24	Option Exercise	21.41	5,000	107,050	33,697	Dec 09 06:28 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Dec 05 '24	Sale	91.49	5,000	457,434	28,697	Dec 09 06:28 PM
PICKERING GRANT	Officer	Dec 09 '24	Proposed Sale	93.68	2,366	221,647		Dec 09 04:07 PM
Eydelman Mikhail	Officer	Dec 05 '24	Proposed Sale	92.75	5,000	463,750		Dec 05 04:04 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Dec 02 '24	Sale	92.45	15,000	1,386,794	450,301	Dec 03 07:15 PM
Wassil Jim	CHIEF OPERATING OFFICER	Dec 02 '24	Option Exercise	2.42	8,000	19,360	213,695	Dec 03 07:13 PM
Wassil Jim	CHIEF OPERATING OFFICER	Dec 02 '24	Sale	92.49	8,000	739,885	205,695	Dec 03 07:13 PM
Wassil Jim	Officer	Dec 02 '24	Proposed Sale	94.01	8,000	752,080		Dec 02 04:07 PM
PICKERING GRANT	Officer	Dec 02 '24	Proposed Sale	94.01	15,000	1,410,150		Dec 02 04:04 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Nov 18 '24	Option Exercise	5.35	8,000	42,800	117,491	Nov 19 04:43 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Nov 18 '24	Sale	85.81	8,000	686,518	109,491	Nov 19 04:43 PM
GUGGENHIME ANDREW	Officer	Nov 18 '24	Proposed Sale	86.50	8,000	692,000		Nov 18 04:02 PM

Open in Screener

ATHA

Athira Pharma Inc

Nov 12 • 04:00PM ET

4.70

+0.07 1.62 %

Healthcare • Biotechnology • USA • NASD

ATHA Athira Pharma Inc daily Stock Chart

Peers: BIIB SAVA AVXL SAGE QURE PRTA INVA AUPH NBIX ANVS

| Held by: SURI VTI VXF DCOR

Index	-	P/E	-	EPS (ttm)	-9.66	Insider Own	7.68%	Shs Outstand	3.94M	Perf Week	12.17%
Market Cap	18.54M	Forward P/E	-	EPS next Y	-5.10	Insider Trans	-15.58%	Shs Float	3.64M	Perf Month	25.67%
Enterprise Value	-5.78M	PEG	-	EPS next Q	-0.84	Inst Own	44.05%	Short Float	1.82%	Perf Quarter	18.06%
Income	-37.72M	P/S	-	EPS this Y	76.41%	Inst Trans	-0.88%	Short Ratio	2.20	Perf Half Y	80.98%
Sales	0.00M	P/B	0.69	EPS next Y	14.21%	ROA	-64.88%	Short Interest	0.07M	Perf YTD	-19.89%
Book/sh	6.79	P/C	0.73	EPS next 5Y	76.92%	ROE	-89.42%	52W High	8.26 -43.13%	Perf Year	-28.78%
Cash/sh	6.40	P/FCF	-	EPS past 3/5Y	-19.25% -73.94%	ROIC	-138.45%	52W Low	2.20 114.08%	Perf 3Y	-84.44%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	9.92% 7.13%	Perf 5Y	-97.93%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	66.10%	Oper. Margin	-	ATR (14)	0.30	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	9.70	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	64.59	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	9.70	EPS Q/Q	77.53%	SMA20	14.09%	Beta	2.95	Target Price	4.00
Payout	-	Debt/Eq	0.03	Sales Q/Q	-	SMA50	17.55%	Rel Volume	0.32	Prev Close	4.62
Employees	26	LT Debt/Eq	0.02	Earnings	Nov 06 AMC	SMA200	29.72%	Avg Volume	30.08K	Price	4.70
IPO	Sep 18, 2020	Option/Short	No / Yes	EPS/Sales Surpr.	-58.49% -	Trades		Volume	9,747	Change	1.62%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-19-24	Downgrade	Mizuho	Outperform → Neutral	$5 → $0.50
Sep-04-24	Downgrade	Rodman & Renshaw	Buy → Neutral
Sep-04-24	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Sep-04-24	Downgrade	BTIG Research	Buy → Neutral
Aug-19-24	Initiated	Rodman & Renshaw	Buy	$22
Oct-17-22	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform	$20
Jul-07-22	Initiated	Mizuho	Buy	$6
Jun-23-22	Downgrade	Stifel	Buy → Hold	$36 → $5
Jun-23-22	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Jun-23-22	Downgrade	Jefferies	Buy → Hold	$32 → $3
May-10-22	Initiated	BTIG Research	Buy	$33
Apr-21-22	Initiated	Berenberg	Buy	$33
Dec-15-21	Initiated	Goldman	Neutral	$16
Oct-13-20	Initiated	Stifel	Buy	$36
Oct-13-20	Initiated	JMP Securities	Mkt Outperform	$51
Oct-13-20	Initiated	Jefferies	Buy	$30
Oct-13-20	Initiated	Goldman	Buy	$53

Show Previous Ratings

Nov-06-25 04:05PM	Athira Pharma Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Sep-11-25 09:00AM	Athira Pharma Announces Reverse Stock Split (GlobeNewswire)
Aug-14-25 07:00AM	Athira Pharma Presents ATH-1105 Phase 1 Trial Results at ALS Nexus 2025 (GlobeNewswire)
Aug-07-25 04:05PM	Athira Pharma Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) +5.95%
May-14-25 11:10AM	Athira Pharma to present data from first-in-human Phase 1 trial of ATH-1105 (TipRanks) -7.25%
11:00AM	Loading…
May-13-25 11:00AM	Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit (GlobeNewswire)
May-09-25 04:05PM	Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates (GlobeNewswire) +6.17%
Feb-27-25 04:05PM	Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates (GlobeNewswire)
Dec-06-24 05:30PM	Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association's 35th International Symposium on ALS/MND (GlobeNewswire)
Nov-08-24 04:50AM	Athira exploring strategic alternatives after Alzheimers failure (BioPharma Dive) -12.01%
Nov-07-24 04:05PM	Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates (GlobeNewswire) +7.14%
Oct-22-24 07:00AM	Athira Pharma to Present Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Meeting (GlobeNewswire) +15.73%
Sep-17-24 09:00AM	Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases (GlobeNewswire)
Sep-04-24 11:40AM	Alzheimers Trial Failure Sends Athira Stock Down 75% (Barrons.com) -78.43%
11:33AM	Athiras stock topples after Alzheimers drug flops in Phase II/III trial (Pharmaceutical Technology)
08:48AM	Loading…
08:48AM	Athira Pharma's Alzheimer's Candidate Fails To Improve Cognition And Function In Patients With Mild/Moderate Disease, Stock Sinks (Benzinga)
Sep-03-24 04:01PM	Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer's Disease (GlobeNewswire) -8.41%
Aug-23-24 09:40AM	Are Medical Stocks Lagging Athira Pharma (ATHA) This Year? (Zacks) +6.75%
Aug-07-24 09:40AM	Is Athira Pharma (ATHA) Stock Outpacing Its Medical Peers This Year? (Zacks)
Aug-01-24 04:05PM	Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates (GlobeNewswire)
Jul-31-24 08:05AM	Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer's Disease-Related Pathology at the Alzheimer's Association International Conference (AAIC) 2024 (GlobeNewswire)
Jul-10-24 08:51AM	Athira (ATHA) Completes Dosing in Alzheimer's Study, Stock Up (Zacks)
Jul-09-24 07:00AM	Athira Pharma Announces Last Patient Completed LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer's Disease (GlobeNewswire) +29.39%
Jun-12-24 07:00AM	Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer's Disease Patients (GlobeNewswire)
Jun-11-24 07:00AM	Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS) (GlobeNewswire)
May-29-24 07:00AM	Athira Pharma to Participate in Upcoming June Conferences (GlobeNewswire)
May-17-24 05:00PM	Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action (GlobeNewswire) -7.01%
May-15-24 10:54PM	ATHA Stock Earnings: Athira Pharma Beats EPS for Q1 2024 (InvestorPlace) +22.62%
04:05PM	Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates (GlobeNewswire)
May-07-24 09:15AM	Sidoti Events, LLC's Virtual May Micro-Cap Conference (ACCESSWIRE) +10.66%
07:00AM	Loading…
May-02-24 07:00AM	Athira Pharma to Participate in Upcoming May Conferences (GlobeNewswire)
Apr-15-24 07:00AM	Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer (GlobeNewswire) -15.57%
Apr-11-24 07:00AM	Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer's Disease (GlobeNewswire) +6.85%
Apr-03-24 07:00AM	Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting (GlobeNewswire)
Mar-08-24 07:00AM	Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer's and Parkinson's Diseases at AD/PD 2024 International Conference (GlobeNewswire) -13.73%
Feb-28-24 12:00PM	Athira Pharma, Inc. (ATHA) is a Great Momentum Stock: Should You Buy? (Zacks)
Feb-22-24 04:05PM	Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates (GlobeNewswire) +6.22%
Feb-15-24 02:56PM	2 Strong Buy Penny Stocks That Could Rally All the Way to $10 (or More) (TipRanks) +12.27%
Feb-08-24 04:02PM	Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS) (GlobeNewswire)
Jan-08-24 07:00AM	Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update (GlobeNewswire) +10.45%
Jan-03-24 07:00AM	Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer's Disease (GlobeNewswire)
Dec-12-23 07:00AM	Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies (GlobeNewswire)
Dec-05-23 10:25AM	Sidoti Events, LLC's Virtual December Small-Cap Conference (ACCESSWIRE)
Nov-29-23 07:00AM	Athira Pharma to Participate in Sidoti December Small Cap Investor Conference (GlobeNewswire)
Nov-28-23 07:00AM	Athira Pharma Announces Upcoming Presentation at Motor Neurone Disease Association's 34 International Symposium on ALS/MND (GlobeNewswire) -5.88%
Nov-15-23 08:15AM	Athira Pharma Presents Preclinical Data Highlighting Fosgonimeton's Neuroprotective Effects Against Amyloid- -Induced Pathological Alterations and Neuroinflammation in Models of Alzheimer's Disease (GlobeNewswire)
Nov-09-23 04:05PM	Athira Pharma Reports Third Quarter 2023 Financial Results and Pipeline and Business Updates (GlobeNewswire) -7.33% +6.47%
Nov-08-23 07:00AM	Athira Pharma to Participate in Jefferies London Healthcare Conference (GlobeNewswire)
Oct-05-23 04:30PM	Athira Pharma Presents Preclinical Data Further Supporting the Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS) (GlobeNewswire)
Sep-28-23 07:00AM	Athira Pharma to Participate in Upcoming October Conferences (GlobeNewswire) +5.26%
Sep-19-23 07:00AM	Athira Pharma to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference (GlobeNewswire)
Sep-08-23 12:00PM	All You Need to Know About Athira Pharma, Inc. (ATHA) Rating Upgrade to Buy (Zacks)
Aug-31-23 09:35AM	Down -24.75% in 4 Weeks, Here's Why You Should You Buy the Dip in Athira Pharma, Inc. (ATHA) (Zacks)
Aug-29-23 09:55AM	Athira Pharma, Inc. (ATHA) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
Aug-10-23 04:05PM	Athira Pharma Reports Second Quarter 2023 Financial Results and Pipeline and Business Updates (GlobeNewswire) +5.21% -7.26%
Jul-17-23 07:00AM	Athira Pharma Presents Phase 2 Clinical Data Correlating Improvements in Biomarkers of Neurodegeneration and Neuroinflammation with Improvements in Measures of Cognition and Function in Alzheimers Disease (GlobeNewswire)
Jul-06-23 11:52AM	Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
07:00AM	Athira Pharma Announces Upcoming Presentations at the Alzheimers Association International Conference (AAIC) 2023 (GlobeNewswire)
Jun-08-23 06:08AM	Andrew Gengos Spends US$192k On Athira Pharma Stock \ (Simply Wall St.)
Jun-07-23 08:10AM	Daily Vickers Top Buyers & Sellers for 06/07/2023 (Argus Research) +12.54%
May-31-23 07:00AM	Athira Pharma to Participate in Upcoming June Conferences (GlobeNewswire)
May-22-23 07:00AM	Athira Pharma Appoints Andrew Gengos as Chief Financial Officer and Chief Business Officer (GlobeNewswire)
May-12-23 11:34AM	FDA Rejects ImmunityBio's (IBRX) Bladder Cancer Therapy Filing (Zacks)
May-11-23 04:05PM	Athira Pharma Reports First Quarter 2023 Financial Results and Recent Pipeline and Business Updates (GlobeNewswire)
12:25PM	Jazz (JAZZ) Lags on Q1 Earnings & Sales, Reaffirms '23 View (Zacks)
May-08-23 07:00AM	Athira Pharma to Participate in Upcoming May Investor Conferences (GlobeNewswire)
Apr-29-23 08:45AM	Athira Pharma, Inc. (NASDAQ:ATHA) is a favorite amongst institutional investors who own 58% (Simply Wall St.)
Apr-25-23 04:01PM	Athira Pharma Presents New Clinical and Preclinical Data at the American Academy of Neurology (AAN) 2023 Annual Meeting (GlobeNewswire)
Apr-11-23 07:00AM	Athira Pharma Announces Upcoming Presentations at the American Academy of Neurology (AAN) 2023 Annual Meeting (GlobeNewswire)
Apr-02-23 08:14AM	Trade Alert: The Independent Director Of Athira Pharma, Inc. (NASDAQ:ATHA), Grant Pickering, Has Just Spent US$60k Buying 3,193% More Shares (Simply Wall St.)
Mar-28-23 12:00PM	Athira Pharma, Inc. (ATHA) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
01:00AM	Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of Fosgonimeton for Alzheimers and Parkinsons Diseases at AD/PD 2023 International Conference (GlobeNewswire)
Mar-23-23 04:05PM	Athira Pharma Reports Full Year 2022 Financial Results and Recent Pipeline and Business Updates (GlobeNewswire)
Mar-08-23 07:00AM	Athira Pharma to Present at Upcoming Neuroscience Focused Investor Conferences (GlobeNewswire)
Mar-06-23 07:00AM	Athira Pharma to Present Data Supporting Therapeutic Potential of Enhancing HGF/MET Neurotrophic System at Upcoming Scientific Conferences (GlobeNewswire)
Feb-01-23 07:00AM	Athira Pharma Announces Publication in Journal of Alzheimers Disease Highlighting Need for Novel Alzheimers Disease Treatment Approaches and Potential of Enhancing HGF/MET Pathway (GlobeNewswire)
Jan-31-23 07:00AM	Athira Pharma Announces Promotion of Kevin Church, Ph.D., to Chief Scientific Officer (GlobeNewswire)
Jan-28-23 08:00AM	How Athira and its former CEO are moving on after controversial split (American City Business Journals)
Jan-27-23 10:08AM	Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Jan-17-23 01:00AM	Former Athira CEO on her controversial exit: 'I was relieved that it came to an end' (American City Business Journals)
Jan-05-23 07:00AM	Athira Pharma Provides 2023 Pipeline Outlook (GlobeNewswire)
Jan-03-23 06:26AM	Daily Vickers Top Buyers & Sellers for 01/03/2023 (Argus Research) +6.62%
Dec-21-22 07:00AM	Athira Pharma Announces Publication of Fosgonimeton Preclinical Results in Neurotherapeutics (GlobeNewswire)
Dec-09-22 05:34AM	Insider Buying: The Athira Pharma, Inc. (NASDAQ:ATHA) Independent Chairwoman of the Board Just Bought 361% More Shares (Simply Wall St.)
Dec-05-22 07:30AM	Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND (GlobeNewswire) -10.37%
Dec-01-22 07:00AM	Athira Pharma to Host Virtual R&D Event on December 7, 2022, from 2:00 3:30 pm Eastern time (GlobeNewswire)
Nov-29-22 11:00AM	Athira Pharma Highlights Therapeutic Potential of Fosgonimeton in Presentation of Additional Biomarker Data in Mild-to-Moderate Alzheimers Disease Patients from ACT-AD Phase 2 Study at CTAD Conference (GlobeNewswire)
Nov-28-22 07:00AM	Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND (GlobeNewswire) -5.02%
Nov-21-22 07:00AM	Athira Pharma to Present Additional Biomarker Data from ACT-AD Phase 2 Study of Fosgonimeton at the 2022 Clinical Trials on Alzheimers Disease (CTAD) Conference (GlobeNewswire)
Nov-16-22 07:00AM	Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of HGF/MET Platform at Neuroscience 2022 Conference (GlobeNewswire)
Nov-10-22 04:05PM	Athira Pharma Reports Third Quarter 2022 Financial Results and Recent Clinical and Corporate Updates (GlobeNewswire) +7.97% +8.39%
Nov-09-22 07:00AM	Athira Pharma to Present at Stifel 2022 Healthcare Conference (GlobeNewswire) -7.07%
Nov-07-22 07:00AM	Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of HGF/MET Platform in Neurodegenerative Disorders at Neuroscience 2022 Conference (GlobeNewswire)
Oct-30-22 08:29AM	Athira Pharma, Inc. (NASDAQ:ATHA) has caught the attention of institutional investors who hold a sizeable 47% stake (Simply Wall St.)
Oct-17-22 07:00AM	Athira Pharma Advances Phase 2/3 LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimers Patients Following Independent, Unblinded Interim Analysis (GlobeNewswire) +9.03%
Sep-16-22 08:14AM	Multiple insiders bought Athira Pharma, Inc. (NASDAQ:ATHA) stock earlier this year, a positive sign for shareholders (Simply Wall St.)
Sep-06-22 03:22PM	Athira Outlines Possible Comeback For Alzheimer's Candidate (Benzinga)
07:00AM	Athira Pharma Provides Update on Plans for Ongoing LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimers Patients (GlobeNewswire)
Aug-20-22 08:01AM	Athira Pharma (NASDAQ:ATHA) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Aug-15-22 04:05PM	Athira Pharma Reports Second Quarter 2022 Financial Results and Recent Clinical and Corporate Updates (GlobeNewswire)

Athira Pharma, Inc. engages in the development of small molecules to restore neuronal health and stop neurodegeneration. Its product pipeline includes ATH-1017, ATH-1019/20, and ATH-1018. The company was founded by Leen Kawas, John Wright, Lewis Rumpler, and Joseph Harding in March 2011 and is headquartered in Bothell, WA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
CHURCH KEVIN	CHIEF SCIENTIFIC OFFICER	Jun 30 '25	Option Exercise	0.00	36,666	0	177,427	Jul 02 04:35 PM
CHURCH KEVIN	CHIEF SCIENTIFIC OFFICER	Jul 01 '25	Sale	0.29	8,526	2,502	168,901	Jul 02 04:35 PM
Litton Mark James	President and CEO	Jun 30 '25	Option Exercise	0.00	108,334	0	350,925	Jul 02 04:34 PM
Litton Mark James	President and CEO	Jul 01 '25	Sale	0.29	25,123	7,374	325,802	Jul 02 04:34 PM
San Martin Javier	CHIEF MEDICAL OFFICER	Jun 30 '25	Option Exercise	0.00	46,666	0	82,507	Jul 02 04:33 PM
San Martin Javier	CHIEF MEDICAL OFFICER	Jul 01 '25	Sale	0.29	10,842	3,182	71,665	Jul 02 04:33 PM
Worthington Mark	General Counsel and CCO	Jun 30 '25	Option Exercise	0.00	36,666	0	120,401	Jul 02 04:33 PM
Worthington Mark	General Counsel and CCO	Jul 01 '25	Sale	0.29	8,526	2,502	111,875	Jul 02 04:33 PM
Renninger Robert	SVP, Finance and Accounting	Jun 30 '25	Option Exercise	0.00	12,359	0	112,083	Jul 02 04:32 PM
Renninger Robert	SVP, Finance and Accounting	Jul 01 '25	Sale	0.29	2,897	850	109,186	Jul 02 04:32 PM
Mark James Litton	Officer	Jul 01 '25	Proposed Sale	0.29	25,123	7,374		Jul 01 07:37 PM
Javier San Martin	Officer	Jul 01 '25	Proposed Sale	0.29	10,842	3,182		Jul 01 07:36 PM
Kevin Church	Officer	Jul 01 '25	Proposed Sale	0.29	8,526	2,502		Jul 01 07:34 PM
Mark Worthington	Officer	Jul 01 '25	Proposed Sale	0.29	8,526	2,502		Jul 01 07:33 PM
San Martin Javier	CHIEF MEDICAL OFFICER	Dec 31 '24	Option Exercise	0.00	46,667	0	46,667	Jan 03 05:05 PM
San Martin Javier	CHIEF MEDICAL OFFICER	Jan 02 '25	Sale	0.56	10,826	6,083	35,841	Jan 03 05:05 PM
Litton Mark James	President and CEO	Dec 31 '24	Option Exercise	0.00	108,333	0	267,698	Jan 03 05:04 PM
Litton Mark James	President and CEO	Jan 02 '25	Sale	0.56	25,107	14,108	242,591	Jan 03 05:04 PM
CHURCH KEVIN	CHIEF SCIENTIFIC OFFICER	Dec 31 '24	Option Exercise	0.00	36,667	0	139,271	Jan 03 05:03 PM
CHURCH KEVIN	CHIEF SCIENTIFIC OFFICER	Jan 02 '25	Sale	0.56	8,510	4,782	130,761	Jan 03 05:03 PM
Renninger Robert	VP of Finance	Dec 31 '24	Option Exercise	0.00	12,359	0	92,605	Jan 03 05:01 PM
Renninger Robert	VP of Finance	Jan 02 '25	Sale	0.56	2,881	1,619	89,724	Jan 03 05:01 PM
Worthington Mark	General Counsel and CCO	Dec 31 '24	Option Exercise	0.00	36,667	0	92,245	Jan 03 05:00 PM
Worthington Mark	General Counsel and CCO	Jan 02 '25	Sale	0.56	8,510	4,782	83,735	Jan 03 05:00 PM
Javier San Martin	Officer	Jan 02 '25	Proposed Sale	0.56	10,826	6,083		Jan 02 08:06 PM
Mark James Litton	Officer	Jan 02 '25	Proposed Sale	0.56	25,107	14,108		Jan 02 08:05 PM
Mark Worthington	Officer	Jan 02 '25	Proposed Sale	0.56	8,510	4,782		Jan 02 08:04 PM
Kevin Church	Officer	Jan 02 '25	Proposed Sale	0.56	8,510	4,782		Jan 02 08:02 PM

PCVX

Vaxcyte Inc

ATHA

Athira Pharma Inc

Upgrade your FINVIZ experience